Annexon, Inc. Files 8-K Report
Ticker: ANNX · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1528115
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
Related Tickers: ANNX
TL;DR
ANNX filed an 8-K, standard reporting stuff.
AI Summary
On October 21, 2024, Annexon, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events detailed in the provided text. The report was filed with the SEC on October 22, 2024.
Why It Matters
This filing indicates Annexon, Inc. is fulfilling its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material information that would inherently increase risk.
Key Players & Entities
- Annexon, Inc. (company) — Registrant
- 0001193125-24-240585 (filing_id) — Accession Number
- 20241021 (date) — Date of earliest event reported
- 20241022 (date) — Filing Date
- 1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, California 94005 (address) — Principal executive offices
- (650) 822-5500 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Annexon, Inc.?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of October 21, 2024.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on October 22, 2024.
What is Annexon, Inc.'s principal executive office address?
Annexon, Inc.'s principal executive office is located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005.
What is the telephone number listed for Annexon, Inc.?
The telephone number listed for Annexon, Inc. is (650) 822-5500.
What is the SIC code for Annexon, Inc.?
The Standard Industrial Classification (SIC) code for Annexon, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-10-21 20:15:58
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ANNX The Nasdaq Stock Mar
Filing Documents
- d849436d8k.htm (8-K) — 24KB
- d849436dex991.htm (EX-99.1) — 21KB
- g849436g1021223518195.jpg (GRAPHIC) — 3KB
- 0001193125-24-240585.txt ( ) — 179KB
- annx-20241021.xsd (EX-101.SCH) — 3KB
- annx-20241021_lab.xml (EX-101.LAB) — 18KB
- annx-20241021_pre.xml (EX-101.PRE) — 11KB
- d849436d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 21, 2024, titled "Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting." 104.1 Cover Page Interactive Data File, formatted in inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 21, 2024 Annexon, Inc. By: /s/ Jennifer Lew Jennifer Lew Executive Vice President and Chief Financial Officer